advertisement

liquisolid tablet of Tamoxifen citrate

50 %
50 %
advertisement
Information about liquisolid tablet of Tamoxifen citrate
Education

Published on October 14, 2012

Author: dnyaneshwalunj

Source: authorstream.com

advertisement

FORMULATION DEVELOPMENT AND EVALUATION OF TAMOXIFEN CITRTE LIQUISOLID SYSTEM: 1 FORMULATION DEVELOPMENT AND EVALUATION OF TAMOXIFEN CITRTE LIQUISOLID SYSTEM Presented by :- Walunj Dnyanesh Ramnath . Under the Guidance of Guide Co-guide Dr. K.S.Bhise Prof. Y. P.Sharma Department of Pharmaceutics SND College of Pharmacy Babhulgaon, Yeola. 2011-2012 PowerPoint Presentation: 2 INTRODUCTION NEED AND OBJECTIVE PLAN OF WORK MATERIAL AND EQUIPMENT DRUG PROFILE RESULT & DISCUSSION SUMMARY & CONCLUSION BIBLIOGRAPHY CONTENTS PowerPoint Presentation: 3 Poorly water-soluble drugs involve many difficulties in the development of pharmaceutical dosage forms for oral delivery systems due to their low bioavailability. Therapeutic effectiveness of a drug depends upon the bioavailability which is dependent on the solubility and dissolution rate of drug molecules. It is believed that better bioavailability of poorly soluble drugs could be achieved when drug is present in solution as in liquisolid formulations. The concept of liquisolid compacts as defined by Spireas et al, (1998) can be used to formulate liquid medication such as oily liquid drug and solutions or suspensions of water-insoluble solid drugs in non-volatile vehicles, into acceptably flowing and compressible powder. INTRODUCTION PowerPoint Presentation: 4 JUSTIFICATION: JUSTIFICATION 5 Tamoxifen citrate is BCS class II drug. Approaches reported to improve drug delivery and solubility of Tamoxifen citrate: 1) Nanoemulsion formulation for transdermal delivery system. 2) Encapsulated Sustained Release Liposomes of Tamoxifen citrate. 3) No work has been reported for liquisolid system of Tamoxifen citrate. 4)Liquisolid system is superior than other systems Simplicity ii) Economical PowerPoint Presentation: 6 Tamoxifen citrate is poorly soluble at normal body condition it is necessary to increase its dissolution rate by using suitable but still economical process. Enhanced bioavailability can be obtained by enhancing solubility. The aim of present study to design and formulate liquisolid tablet of Tamoxifen citrate. To enhance the solubility of Tamoxifen citrate by using liquisolid method. To enhance the dissolution rate of poorly water-soluble drug using liquisolid technique. To study dissolution profile of optimized liquisolid tablet of Tamoxifen citrate and compare with plain drug and marketed tablet. Need AND OBJECTIVES PowerPoint Presentation: 7 Literature Survey Selection and Procurement of drug and excipients Material and method Preformulation study of drug Formulation and design liquisolid powder system Drug-excipient compatibility study Precompression study Formulation and Development of Liquisolid Tablets Evaluation of liquisolid tablet Stability study PLAN OF WORK PowerPoint Presentation: MATERIALS 8 Sr .No. Name of the ingredient Name of the Supplier 1 Tamoxifen Citrate Gift sample from Apurva Biopharm INC Mumbai. 2 Microcrystalline cellulose ( Avicel PH 102) Product of SD fine chemicals, Mumbai. 3 Colloidal silicone dioxide (Aerosil 200) Product of SD fine chemicals Mumbai. 4 Propylene glycol Product of SD fine chemicals Mumbai. 5 Polyethylene glycol Product of SD fine chemicals Mumbai. 6 Tween 80 Product of SD fine chemicals Mumbai. 7 Tween 20 Product of SD fine chemicals Mumbai. 8 Glycerin Product of SD fine chemicals Mumbai. 9 Sodium starch glycolate Product of SD fine chemicals Mumbai. 10 Magnesium stearate Product of SD fine chemicals Mumbai. MATERIALS and equipment PowerPoint Presentation: 9 EQUIPMENTS Sr.No. Name of equipments Model / make 1 Single pan electronic balance PGB 200,Vensar, India. 2 Rotary shaker C 80, Remi, India. 3 USP dissolution apparatus I TDT-08L, Electrolab, India. 4 Multiple punch tablet compression machine Labpress,CIP, India. 5 Hardness tester VHT-1,Veego, India. 6 Friability tester EF-1W, Electrolab, India. 7 Tablet disintegrating test apparatus ED-2AL, Electrolab, India. 8 Tapped density apparatus ETD 1060, Electrolab, India. 9 Stability chamber CHM-6S,Remi, India. 10 UV Visible Spectrophotometer 2600,Chemito , India. 11 FTIR spectrophotometer 84005,Shimadzu,Japan. 12 X-ray diffractometer D8 Advanced, BRUKER axs, Japan. 13 Differential scanning calorimeter DSC 60, Shimadzu, Japan. DRUG PROFILE: DRUG PROFILE 10 Appearance White crystalline powder Colour White. Molecular weight 563.6 Molecular formula : C 32 H 37 NO 8 Chemical IUPAC Name (2-{4-[(1Z)-1,2-diphenylbut-1-en-1- yl ]phenoxy}ethyl) dimethylamine Chemical Structure: PowerPoint Presentation: 11 BCS class II Dose 20 to 40 mg per day Drug Category Anti-oestrogen Half Life 5 to 7 days Melting point 140 o C-144 o C PowerPoint Presentation: 12 PREFORMULATION STUDIES OF DRUG Identification test: Identification test Results of sample obtained Reported standards Appearance Crystalline powder Crystalline powder Colour White to offwhite White to offwhite Melting point 141-142 0 C 140 – 144 0 C Odour Odourless Odourless METHODOLOGY AND RESULT DISCUSSSION PowerPoint Presentation: 13 Preparation of standard calibration curve of Tamoxifen citrate in Methanol: Sr. No Concentration (µg/ml) Absorbance 1. 2 0.094 ± 0.0005 2. 4 0.191 ± 0.000 3. 6 0.271±0.003 4. 8 0.363±0.002 5. 10 0.443±0.0005 6. 12 0.543 ±0.0005 Preparation of standard calibration curve of Tamoxifen citrate in 0.02 N Hydrochloric Acid:: Preparation of standard calibration curve of Tamoxifen citrate in 0.02 N Hydrochloric Acid: 14 Sr. No Concentration (µg/ml) Absorbance 1. 2 0.044 ±0.0005 2. 4 0.095 ±0.0005 3. 6 0.148 ±0.002 4. 8 0.197 ±0.0005 5. 10 0.245 ±0.003 Fourier Transform Infra Red (FTIR) spectroscopy: : Fourier Transform Infra Red (FTIR) spectroscopy: 15 Sr. No. Functional group Standard IR Range (cm -1 ) Observed wave number(cm -1 ) 1 C=C stretching 1600-1475 1475.59 2 C=O stretching 1730-1700 1728.28 3 -NH 2 3500-3100 3433.41 4 =C-H stretching 3050-3000 3024.48 5 CH 2 stretching 3000-2850 2929.97 DSC thermogram of tamoxifen citrate:: DSC thermogram of tamoxifen citrate: 16 The thermogram of Tamoxifen citrate showed peak indicating the melting point of the drug is 144.56 o C which is identically near to the melting point mentioned in standards. The data proves purity of the drug. X-ray powder diffraction (XRD):: X-ray powder diffraction (XRD): 17 X-ray diffraction pattern reveals the crystalline nature of Tamoxifen citrate Solubility of Tamoxifen citrate in various solvents: : Solubility of Tamoxifen citrate in various solvents: 18 Sr. No. Solvent Solubility (%)w/v 1 PG 10.4 ±0.72 2 Glycerin 2.38 ±0.23 3 Tween 20 3.36 ±0.56 4 Tween 80 2.8 ±0.87 5 PEG 400 3.68 ±0.43 PowerPoint Presentation: 19 DRUG-EXCIPIENT COMPATIBILITY STUDY FOURIER TRANSFORM INFRA RED (FTIR) SPECTROSCOPY: : FOURIER TRANSFORM INFRA RED (FTIR) SPECTROSCOPY: 20 FTIR spectra of pure Tamoxifen citrate FTIR spectrum of Tamoxifen citrate with physical mixture FTIR spectrum of Tamoxifen citrate with precompressible blend DIFFERENTIAL SCANNING CALORIMETRY (DSC):: DIFFERENTIAL SCANNING CALORIMETRY (DSC): 21 DSC thermogram of Tamoxifen citrate DSC thermogram of liquisolid physical mixture (1:1:1) PowerPoint Presentation: 22 DSC thermogram of liquisolid precompressible blend On the other hand, the liquisolid system thermogram in Figure displayed complete disappearance of both characteristic peaks of Tamoxifen citrate, a fact that agrees with the formation of drug solution in the liquisolid powdered system, i.e., the drug was molecularly dispersed within the liquisolid matrix . X-RAY POWDER DIFFRACTION (XRD): : X-RAY POWDER DIFFRACTION (XRD): 23 XRD pattern of A) Tamoxifen citrate B) Physical mixture (1:1:1) C) Precompressible blend. The spectrums of physical mixture were characterized by absence of prominent peaks of Tamoxifen citrate, suggesting that Tamoxifen citrate is present in amorphous form. PowerPoint Presentation: 24 FORMULATION DESIGN Calculations for Liquisolid Flowability (LSF) Test: : Calculations for Liquisolid Flowability (LSF) Test: 25 Composition of powder admixture of various excipient ratios. Sr. No. Excipients ratio (R) Carrier Coating material Total 1 5:1 8.35 1.65 10 2 10:1 9.098 0.902 10 3 15:1 9.37 0.63 10 4 20:1 9.52 0.48 10 Observation table of LSF test : Observation table of LSF test 26 Excipient ratio Cw Angle of repose 1/R Ф value of carrier material Ф value of coating material 5 0.0535 44.43 0.2 0.17 3.33 10 0.118 42.27 0.1 15 0.158 47.32 0.06 20 0.250 48.64 0.05 Φ L f = 0.17 + 3.33 ⋅ (1/ R) Liquisolid compressibility (LSC) test : Liquisolid compressibility (LSC) test 27 Excipient ratio Crushing strength Sc Cw Pactisity Ω Ψ value of carrier material ψ value of coating material 10 3.9 0.035 14.94 0.280 1.91 15 3.8 0.052 14.61 20 2.8 0.076 10.56 Ψ L f = 0.28 +1.91 (1/ R) Composition of different Tamoxifen citrate liquisolid compacts according to Mathematical model. : Composition of different Tamoxifen citrate liquisolid compacts according to Mathematical model. 28 Liquisol system Liquid load factor (L f ) Powder Excipient ratio(R) Q:q Avicel 102 (Q) Aerosil 200 (q) Mg. stearate Liquid medication CCS Tablet weight Quantity in mg mg LS-1 0.518 8 285.12 35.54 4.31 147.9 23.45 496.95 LS-2 0.492 9 300.60 33.40 4.52 147.9 24.09 510.51 LS-3 0.503 10 294.00 29.40 4.71 147.9 24.60 522.43 LS-4 0.472 11 326.00 29.60 4.89 147.9 25.17 533.56 LS-5 0.447 12 330.50 27.50 5.03 147.9 25.50 536.05 LS-6 0.426 13 347.10 26.70 5.21 147.9 26.08 552.99 LS-7 0.406 14 367.28 26.02 5.38 147.9 26.91 570.49 LS-8 0.392 15 377.29 25.15 5.50 147.9 27.51 583.35 LS-9 0.378 16 391.26 24.45 5.63 147.9 28.18 597.42 LS-10 0.365 17 405.20 23.83 5.76 147.9 28.84 611.53 LS-11 0.355 18 416.61 24.50 5.89 147.9 29.45 624.43 LS-12 0.345 19 428.69 22.50 5.99 147.9 29.95 635.03 An appropriate amount of liquid medication containing 10 mg Tamoxifen citrate incorporated in Propylene glycol in each formulation. EVALUATION OF PRECOMPRESSIBLE BLEND: EVALUATION OF PRECOMPRESSIBLE BLEND 29 Flowability parameters of Tamoxifen citrate liquisolid powder system Liquisolid powder Angle of repose Density Hauseners Ratio Carr’s index Bulk density Tapped density LS-1 47.98 ±0.04 0.345 ±0.004 0.455 ±0.001 1.32 ±0.01 24.18 ±1.99 LS-2 44.79 ±1.27 0.278 ±0.002 0.400 ±0.001 1.44 ±0.02 30.50 ±0.56 LS-3 46.12 ±0.64 0.357 ±0.001 0.500 ±0.002 1.40 ±0.02 28.60 ±1.85 LS-4 37.56 ±0.24 0.307 ±0.004 0.412 ±0.003 1.02 ±0.01 18.21 ±0.57 LS-5 42.25 ±1.77 0.313 ±0.004 0.435 ±0.001 1.39 ±0.03 28.05 ±0.97 LS-6 37.99 ±0.35 0.395 ±0.002 0.411 ±0.005 1.28 ±0.01 15.97 ±1.00 LS-7 42.27 ±0.29 0.295 ±0.003 0.417 ±0.003 1.41 ±0.03 29.26 ±1.00 LS-8 33.69 ±0.20 0.357 ±0.001 0.455 ±0.002 1.27 ±0.02 21.52 ±0.74 LS-9 37.56 ±0.18 0.345 ±0.001 0.417 ±0.002 1.21 ±0.02 17.27 ±2.02 LS-10 34.07 ±0.09 0.417 ±0.003 0.476 ±0.001 1.14 0.00 12.97 ±0.98 LS-11 38.84 ±0.49 0.385 ±0.003 0.476 ±0.004 1.20 ±0.01 19.10 ±2.01 LS-12 34.77 ±0.43 0.313 ±0.004 0.400 ±0.004 1.28 ±0.02 21.75 ±0.58 EVALUATION OF LIQUISOLID TABLETS : EVALUATION OF LIQUISOLID TABLETS 30 Formulation No. Thickness (mm) Hardness (kg/cm 2 ) Average Weight Variation (mg) Friability (%) Drug Content ( %) Disintegration Time (Sec) LS-1 2.1 ±0.1 4.6 ±0.32 501.35 ±0.20 0.417 ±0.002 92.08 ±0.86 160 ±1 LS-2 2.5 ±0.2 4.4 ±0.20 515.53 ±0.32 0.320 ±0.001 92.50 ±0.65 178 ±3 LS-3 3.3 ±0.23 4.8 ±0.28 525.98 ±0.22 0.324 ±0.003 93.33 ±0.60 165 ±4 LS-4 3.3 ±0.01 5.4 ±0.25 533.67 ±0.48 0.329 ±0.003 93.75 ±0.73 140 ±1 LS-5 3.4 ±0.01 5.3 ±0.05 539.15 ±0.20 0.416 ±0.001 94.16 ±0.65 160 ±3 LS-6 3.5 ±0.01 5.6 ±0.10 555.17 ±0.42 0.425 ±0.002 93.30 ±0.46 130 ±2 LS-7 3.6 ±0.03 5.8 ±0.20 574.89 ±0.20 0.418 ±0.004 94.50 ±0.73 149 ±1 LS-8 3.7 ±0.05 6.1 ±0.00 588.35 ±0.40 0.233 ±0.001 95.41 ±0.86 155 ±4 LS-9 4.1 ±0.02 6.0 ±0.10 601.12 ±0.20 0.256 ±0.002 95.83 ±0.65 130 ±3 LS-10 4.4 ±0.02 6.2 ±0.25 619.63 ±0.32 0.207±0.003 96.66 ±0.65 155 ±3 LS-11 4.4 ±0.01 6.3 ±0.04 632.13 ±0.42 0.232 ±0.00 94.16 ±0.86 145 ±1 LS-12 4.5 ±0.02 6.3 ±0.05 645.43 ±0.50 0.245 ±0.002 95.87±0.60 150 ±2 In vitro drug release : : In vitro drug release : 31 In-vitro release profile of liquisolid system LS-1 to LS- 6 in 0.02 N HCl Formulation Code Cumulative Percent drug release at time (min) 5 10 20 30 40 50 60 LS - 1 52.29 ±1.03 55.55 ±2.43 64.25 ± 2.34 70.06 ± 1.23 72.60 ± 1.13 74.41 ± 1.48 76.59 ± 2.53 LS - 2 52.65 ±1.43 56.64 ±1.73 63.53 ±2.63 70.78 ±2.98 73.32 ±1.17 75.13 ±1.46 78.40 ±1.98 LS - 3 54.46 ±2.49 58.81 ±1.33 67.52 ±1.33 73.68 ±1.43 76.95 ±2.49 79.85 ±2.78 81.30 ±1.73 LS - 4 55.19 ±1.73 59.54 ±1.21 68.24 ±1.76 74.77 ±1.17 78.76 ±1.22 82.39 ±1.43 83.84 ±2.86 LS - 5 56.64 ±1.76 59.90 ± 2.78 67.16 ±2.03 75.13 ±2.83 79.85 ±1.43 83.11 ±1.22 85.65 ±1.43 LS - 6 58.81 ±1.43 62.08 ±1.17 69.33 ±1.76 75.139 ± 1.43 80.21 ±1.76 85.29 ±2.86 87.83 ±1.76 : 32 Formulation Code Cumulative Percent drug release at time (min) 5 10 20 30 40 50 60 LS7 59.54 ±1.73 62.80 ±2.86 70.06 ±1.68 76.59 ±2.73 81.30 ±1.76 86.38 ±1.43 90.37 ±1.68 LS8 59.96 ±1.22 63.53 ±2.03 70.78 ±1.43 79.85 ±1.68 84.20 ±2.03 88.92 ±1.32 92.54 ±3.03 LS9 62.08 ±1.47 65.34 ±1.76 73.32 ±3.53 81.66 ±2.73 86.74 ±1.68 91.09 ±1.22 94.36 ±1.03 LS10 65.34 ±2.32 70.42 ±1.43 78.76 ±1.68 85.65 ±3.04 87.83 ±2.45 92.9 1 ±2.03 96.90 ±3.44 LS11 65.34 ±2.03 68.97 ±2.03 78.40 ±1.17 83.11 ±1.76 87.47 ±1.47 91.09 ±1.47 95.81 ±1.73 LS12 64.62 ±1.68 70.06 ±1.68 77.31 ±2.03 81.66 ±3.44 85.65 ±1.22 91.82 ±1.03 94.36 ±2.73 In-vitro release profile of liquisolid system LS-7 to LS- 12 in 0.02 N HCl In-vitro release profile of optimized batch and marketed tablet and pure drug in 0.02 N HCl : In-vitro release profile of optimized batch and marketed tablet and pure drug in 0.02 N HCl 33 Formulation Code Cumulative Percent drug release at time (min) 5 10 20 30 40 50 60 LS10 65.34 ±2.32 70.42 ±1.43 78.76 ±1.68 85.65 ±3.04 87.83 ±2.45 92.9 1 ±2.03 96.90 ±3.44 Marketed Tablet 55.55 ±2.73 57.00 ±1.76 61.72 ±1.68 65.70 ±2.45 67.16 ±1.68 68.97 ±2.03 70.42 ±2.45 Pure Drug 6.69 ±2.03 8.65 ±1.73 12.72 ±2.17 16.63 ±1.47 19.10 ±2.73 22.25 ±2.45 25.48 ±2.32 Comparative release pattern of liquisolid system LS 10, marketed tablet and pure drug: : Comparative release pattern of liquisolid system LS 10, marketed tablet and pure drug: 34 Stability Study:: Stability Study: 35 Evaluation of formulation (LS-10) kept for stability at 40 0 C /75%RH as per ICH guidelines. Parameters 0 day 15 days 30 days 45 days 60 days Appearance Offwhite Offwhite Offwhite Offwhite Offwhite Hardness (Kg/cm 2 ) 6.2 ±0.25 6.2 ±0.04 6.2 ±0.28 6.2 ±0.25 6.0 ±0.28 Drug content (%) 96.66 ± 0.65 96.66 ±0.05 96.6 ±0.05 95.76 ±0.65 95.5 ±0.07 Friability 0.207 ± 0.003 0.207±0.005 0.207±0.003 0.206±0.007 0.206±0.005 Disintegration test (seconds) 155 ±1 155 ±2 155 ±1 134 134 ±3 In-vitro drug release study of formulation (LS-10) kept for stability at 400C 75%RH :: In-vitro drug release study of formulation (LS-10) kept for stability at 40 0 C 75%RH : 36 Time (MIN) Cumulative % drug released 0 day 15 days 30 days 45 days 60 days 5 65.34 ±2.32 65.34 ±2.32 65.32 ±1.68 64.36 ±1.32 64.36 ±3.03 10 70.42 ±1.43 70.42 ±1.32 70.42 ±1.03 68.42 ±2.45 68.42 ±3.44 20 78.76 ±1.68 78.76 ±2.45 78.76 ±3.44 78.76 ±3.04 78.76 ±2.32 30 85.65±3.04 85.65 ±2.32 85.65 ±2.45 85.65 ±2.03 85.65 ±2.45 40 87.83±2.45 87.83 ±2.03 87.83 ±3.44 87.83 ±2.45 86.33 ±1.32 50 92.90±2.03 92.90±2.32 92.90 ±1.32 92.90 ±1.03 92.75 ±2.32 60 96.90 ±3.44 96.90 ±2.86 96.90 ±3.44 96.90 ±2.32 95.80 ±2.45 CONCLUSION: CONCLUSION 37 The Liquisolid technique is a promising alternative for improvement of dissolution property of water-insoluble drugs, such as Tamoxifen citrate. The enhanced rate of Tamoxifen citrate dissolution from liquisolid tablets was probably due to an increase in wetting properties and surface area of drug particles available for dissolution. It is held within the powder substrate in solution or, in a solubilized, almost molecularly dispersed state, which contributes to the enhanced drug dissolution properties. PowerPoint Presentation: 38 As compared to the pure drug and marketed tablet, liquisolid compacts of Tamoxifen citrate displayed significantly enhanced in vitro drug release properties. The powder excipient ratio was directly proportional to the in vitro release of Tamoxifen citrate from liquisolid formulations. In conclusion, development of the liquisolid compacts can be a promising alternative technique for BCS class II and IV drugs to achieve the improved dissolution rate. Thus the study reveals that the aqueous solubility of Tamoxifen citrate was improved by using Liquisolid system. Future Prospective: Future Prospective 39 Promising tool to improve the aqueous drug solubility that can be commercialized. publication: publication 40 REFERENCES: REFERENCES 41 Spireas, S., Sadu, S. and Grover, R. 1998. “In vitro release evaluation of hydrocortisone liquisolid tablets.” Journal of Pharmaceutical Science 87: 867–872. Spireas, S., Wang, T. and Grover, R. 1999. “Effect of powder substrate on the dissolution properties of methchrothiazide liquisolid compacts.” Drug Development and Industrial Pharmacy 25 : 163–168. Spireas, S. and Sadu, S. 1998. “Enhancement of prednisolone dissolution properties using liquisolid compacts.” International Journal of Pharmaceutics 166: 177–188. Srinivas, V., Sateesh, K.V., Vijay, K.B. and Prasad, G. 2012. “Liquisolid Compacts: An Approach to Enhance the Dissolution Rate of Nimsulide.” Journal of Applied Pharmaceutical Science 02 (05): 115-121. United States pharmacopoeia 30 National formulary 25. 2007. Asian ed., United States Pharmacopeial convention, Inc. 25: 242, 277, 643. 3268, 3269 Tiong, N. and Elkordy, A.A. 2009. “Effects of liquisolid formulations on dissolution of Naproxen.” European Journal of and Biopharmaceutics 73:373–384. PowerPoint Presentation: 42 7. Yadav, V.B. 2010. “Enhancement of Solubility and Dissolution Rate of BCS class II Pharmaceuticals by Nonaqueous Granulation Technique.” International journal of pharmaceutical research and development 12(1): 1-12. Yadav, V.B., Nighute, A.B., Yadav, A.V. and Bhise S.B. 2009. “Aceclofenac Size Enlargement by Non Aqueous Granulation with Improved Solubility and Dissolution.” Archives Pharmaceutical Science and Research 1 (2): 115 – 122. Adhyapak, A. and Desai, B.G. 2011. “Preparation and in vitro characterization of the transdermal drug delivery system containing Tamoxifen citrate for breast cancer.” Asian Journal of Pharmaceutics 5(1):41-45. Aguiar, A. J., Zelmer, A. J. and Kinkel, A. W. 1967. “Deagglomeration behavior of relatively insoluble benzoic acid and its sodium salt.” Journal of Pharmaceutical Science 56:1243–1252. Ali, N., Roya A., Desaia, S. and Javadzadeh, Y. 2010. “Liquisolid compacts: The effect of cosolvent and HPMC on Theophylline release.” Colloids and Surfaces B: Biointerfaces 79: 262–269. Babatunde, A., Amal, A., Ebtessam, A. and Essa, S.E. 2010. “ Liquisolid Systems to Improve the Dissolution of Furosemide.” Scientia Pharmaceutica 78: 325–344. Boghra, R., Patel, A., Desai, H. and Jadhav, A. 2011. “Formulation and evalution of Irbesartan liquisolid tablets.” International Journal of Pharmaceutical Sciences Review and Research 9(2):32-37. PowerPoint Presentation: Thank you 43

Add a comment

Comments

http://www.mohawklanes.com/leagu | 14/12/14
cheap custom jerseys wholesale from china, buy customized sports jerseys free shipping. [url=http://www.mohawklanes.com/leagues.html]http://www.mohawklanes.com/leagues.html[/url]
http://www.countrylanesludington | 12/12/14
Purchase pro bowl football jerseys,buy Nike Pro Bowl jerseys at best Prices.We have various kinds of jerseys in different sizes and colors for you to choose. http://www.countrylanesludington.com/support.html http://www.countrylanesludington.com/support.html

Related presentations

Related pages

DailyMed - NOLVADEX- tamoxifen citrate tablet

NOLVADEX® (tamoxifen citrate) Tablets, a nonsteroidal antiestrogen, are for oral administration. NOLVADEX Tablets are available as:
Read more

Tamoxifen Citrate - Drug InfoNet - Newsfeed - [general]

Tamoxifen Citrate Tablets, ... events occurring when cytotoxic agents are used in combination with Tamoxifen Citrate Tablets. Tamoxifen, ...
Read more

DailyMed - TAMOXIFEN CITRATE- tamoxifen citrate tablet ...

Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast ... TAMOXIFEN CITRATE- tamoxifen citrate tablet, ...
Read more

TAMOXIFEN 20 MG TABLETS PL 02142/0050 - Medicines and ...

product Tamoxifen 20 mg Tablets ... Each tablet contains 20 mg tamoxifen (as citrate). For the full list of excipients, see 6.1. 3 PHARMACEUTICAL FORM
Read more

Tamoxifen 20mg Tablets PL 20395/0010 - Medicines and ...

MHRA PAR; TAMOXIFEN 20MG TABLETS, PL 20395/0010 1 Tamoxifen 20mg Tablets ... 1 tablet contains 30.4mg tamoxifen citrate (equivalent to 20mg tamoxifen).
Read more

Side Effects of Nolvadex (Tamoxifen Citrate) Drug Center ...

The following table summarizes the incidence of adverse reactions reported at a frequency of 2% or greater from clinical ... (tamoxifen citrate) ...
Read more

TAMOXIFEN TABLETS 20MG | Drugs.com

Each 10mg tablet contains 15.2mg of Tamoxifen citrate. Each 20mg tablet contains 30.4mg of Tamoxifen citrate. ... Tamoxifen Tablets 20mg: PL 11311/0059
Read more

Tamoxifen Citrate - National Cancer Institute

Tamoxifen citrate is also being studied in the treatment of other types of . More About Tamoxifen Citrate. ... The Study of Tamoxifen and Raloxifene ...
Read more